Search

everythinglearnresearchcommunity

for

Search:↓

Ginsenoside compound K shows promise for treating metabolic diseases like obesity and diabetes, but more research is needed on its safety and effectiveness.

PF-05314882 selectively activates androgen receptors without much effect on prostate and may help in prostate cancer treatment and hair loss prevention.

GLP-1 receptor agonists can help manage PCOS metabolism but need careful use before conception.

LGD1069 effectively prevents breast tumors in mice without toxicity.

20(S)-Protopanaxadiol-aglycone may help prevent and treat prostate cancer by reducing androgen receptor activity.

GLP-1 receptor agonists help women with PCOS lose weight and improve health, but more research is needed on long-term effects.

A new small peptide may help hair growth by activating a specific receptor and should be tested in humans.

GLP-1 receptor agonists, like Dulaglutide, Liraglutide, and Semaglutide, have potential benefits beyond the pancreas, including neuroprotection, pain suppression, cardiovascular protection, obesity management, and cancer treatment, but there are concerns about pancreatitis and pancreatic cancer risks.

GLP-1 receptor analogs may help improve metabolism and reproductive health in people with PCOS and obesity.

Formyl-peptide receptor agonists could be new anti-inflammatory drugs.

Breast cancer treatments work better with AR activation, improving results and reducing side effects.

Two new compounds can block androgen receptor activity in different ways and may lead to new treatments for androgen-related diseases.

Blocking glucocorticoid receptors improves glucose metabolism in a PCOS mouse model.

GLP-1 receptor agonists can cause skin reactions, facial fat loss, and hair loss, but may help with wound healing and skin conditions.

GLP-1 receptor agonists help with weight loss but need to be combined with other treatments for best results.

Mice skin has components that could help with hair growth and might be used for diabetes treatment.

GLP-1 agonists may help treat certain skin conditions.

GLP-1RA therapy may increase the risk of hair loss.

Allopregnanolone is needed for certain brain processing issues caused by D1 dopamine receptor activation.

RXR agonists may promote hair growth in humans.

dAR-6–1 is a promising new treatment for hair loss that works better than minoxidil.

GLP-1 receptor agonists may cause hair loss, but regrowth is rare.

Allopregnanolone increases growth and changes gene activity in human brain cancer cells.

Chronic GnRHa treatment can help manage endometrial hyperplasia and reduce ovarian androgen excess in PCO patients.

Enobosarm may effectively treat androgen receptor-positive breast cancer with fewer side effects.

Agouti and AGRP affect pigmentation and obesity, with implications for metabolic disorders.

Inhibiting PDE8A may help treat hair loss by boosting fat cell growth and hair regeneration.

Plerixafor may help treat pigmentation disorders by promoting skin repigmentation.

GLP-1 receptor agonists may cause hair loss, but more research is needed.